Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Enterprise Value (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Enterprise Value for 7 consecutive years, with -$3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 51.0% to -$3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.1 million, a 51.0% increase, with the full-year FY2024 number at -$6.3 million, down 281.01% from a year prior.
  • Enterprise Value was -$3.1 million for Q3 2025 at Vivos Therapeutics, up from -$4.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$988000.0 in Q3 2023 to a low of -$34.2 million in Q2 2021.
  • A 5-year average of -$9.8 million and a median of -$6.3 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: soared 85.34% in 2022, then crashed 537.65% in 2024.
  • Vivos Therapeutics' Enterprise Value stood at -$24.0 million in 2021, then skyrocketed by 85.34% to -$3.5 million in 2022, then surged by 53.31% to -$1.6 million in 2023, then tumbled by 281.01% to -$6.3 million in 2024, then soared by 50.69% to -$3.1 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Enterprise Value are -$3.1 million (Q3 2025), -$4.4 million (Q2 2025), and -$2.3 million (Q1 2025).